|
gptkbp:instance_of
|
gptkb:biotechnology
|
|
gptkbp:acquisition
|
gptkb:Just_Biotherapeutics
gptkb:Celerion
gptkb:Krebsforschung_Gmb_H
Oxford Drug Design
Sanofi's drug discovery unit
|
|
gptkbp:awards
|
Best Place to Work (2021)
Sustainability Award (2022)
Innovation Award (2022)
Best Contract Research Organization (2020)
Top 10 Biotech Companies (2021)
|
|
gptkbp:ceo
|
Cord Dohrmann
|
|
gptkbp:clinical_trial
|
Phase III trials
Regulatory submissions
Phase I trials
Phase II trials
Preclinical studies
|
|
gptkbp:collaborations
|
gptkb:Bill_&_Melinda_Gates_Foundation
gptkb:European_Union
gptkb:National_Institutes_of_Health
gptkb:Wellcome_Trust
gptkb:Innovative_Medicines_Initiative
|
|
gptkbp:employees
|
~2,000
|
|
gptkbp:founded
|
gptkb:1993
|
|
gptkbp:headquarters
|
gptkb:Hamburg,_Germany
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Evotec AG
|
|
gptkbp:industry
|
Pharmaceuticals
|
|
gptkbp:invention
|
~1,000 patents filed
|
|
gptkbp:market_cap
|
~€ 2 billion (2021)
|
|
gptkbp:net_income
|
€ 30 million (2020)
|
|
gptkbp:partnerships
|
gptkb:Sanofi
gptkb:Bayer_AG
gptkb:Boehringer_Ingelheim
gptkb:Bristol-Myers_Squibb
gptkb:Celgene
|
|
gptkbp:research_focus
|
gptkb:Oncology
Immunology
Neuroscience
Infectious diseases
Metabolic diseases
|
|
gptkbp:revenue
|
€ 300 million (2020)
|
|
gptkbp:services
|
Drug discovery
Development services
|
|
gptkbp:stock_symbol
|
EVT
|
|
gptkbp:subsidiaries
|
gptkb:Evotec_(UK)_Limited
gptkb:Evotec_(France)_SAS
gptkb:Evotec_(Germany)_Gmb_H
|
|
gptkbp:website
|
www.evotec.com
|
|
gptkbp:bfsParent
|
gptkb:Bayer_AG
gptkb:Bayer
|
|
gptkbp:bfsLayer
|
5
|